Fanhua BluePlus Forms Strategic Partnerships with Shanghai Biotecan Pharmaceuticals Page 1

GUANGZHOU, China, Sept. 6, 2024 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “FANHUA”), a leading independent technology-driven financial services company in China, today announced that it, through its wholly-owned subsidiary Fanhua BluePlus Health Management Co., Ltd. (“Fanhua BluePlus”), recently signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals Co. Ltd. (“Biotecan”).

Under the strategic cooperation agreement, Fanhua BluePlus and Biotecan will leverage their respective resources and service strengths to work together on advanced medical testing, health management, cell therapy and other modern, high-quality medical and health management services.